NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
NASDAQ · IMAB · USD
Stock price, earnings
Quote as of Mar 17, 2026, 01:30 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
I-Mab’s quoted price sits in the lower half of its reported 52-week range, 57.58% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow I-Mab’s reporting calendar.
THE COMPANY BEHIND THE TICKER
I-Mab is a biopharmaceutical company, operating at the clinical stage, dedicated to the discovery, advancement, and commercialization of biologic therapies. Its core mission is to address critical medical needs in both oncology and autoimmune diseases. The company boasts a comprehensive pipeline of drug candidates. Among its most advanced programs, Eftansomatropin alfa, a long-acting human growth hormone, has successfully completed Phase 3 clinical trials for pediatric growth hormone deficiency. Similarly, Lemzoparlimab, a CD47 monoclonal antibody, has concluded its Phase 2 clinical evaluation. Other notable assets include Felzartamab, a CD38 antibody currently undergoing Phase 1b/2a development for membranous nephropathy. Both TJ107 and Efineptakin (a long-acting variant), recombinant human IL-7 therapies, are progressing through Phase 2 for cancer treatment-related lymphopenia and immunotherapy applications. The pipeline further comprises Enoblituzumab, a humanized B7-H3 antibody in Phase 2 for head and neck cancer and other malignancies; Uliledlimab, a CD73 antibody, also in Phase 2 for solid tumors; and TJ210, a monoclonal antibody against human C5aR1, which is in Phase 1 for cancer and autoimmune disorders. I-Mab's portfolio also features Plonmarlimab, a GM-CSF monoclonal antibody intended for inflammation and CRS-related therapies, alongside several specialized oncology agents: TJ-L14B (a PD-L1-based tumor-dependent T-cell engager for solid cancers), TJ-CD4B (a tumor-dependent T-cell engager for gastric and other cancers), TJ-L1IF (a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors), and TJ-C64B (a tumor-dependent T-cell engager for ovarian and other cancers). To bolster its development efforts, I-Mab has forged strategic alliances with leading industry partners, including AbbVie Ireland Unlimited Company, Sinopharm Group Co. Ltd., PT Kalbe Genexine Biologics, and Roche Diagnostics. Established in 2014, the company's headquarters are located in Shanghai, People's Republic of China.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:55 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Mar 29, 2024 |
| -$0.03+95.86% vs estimate |
| $0.00-100.0% vs estimate |
| Q4 2023 | Mar 14, 2024 | -$0.06+41.68% vs estimate | $164.16K-99.06% vs estimate |
|---|
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
THE ANALYST VIEW
5 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$14.98-$0.14 (-0.93%)
Erasca, Inc.’s quoted price sits in the upper half of its reported 52-week range, 38.3% below the high.
$22.30-$0.23 (-1.02%)
Legend Biotech Corporation’s quoted price sits in the lower half of its reported 52-week range, 40.53% below the high.
$22.36-$0.68 (-2.95%)
Zai Lab Limited’s quoted price sits in the upper half of its reported 52-week range, 18.69% below the high.
$15.45-$0.11 (-0.71%)
Cullinan Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 33.38% below the high.
$3.30-$0.10 (-2.8%)
C4 Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 36.17% below the high.
$1.22+$0.04 (+3.39%)
ALX Oncology Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.14% below the high.
$11.05-$1.21 (-9.87%)
Burning Rock Biotech Limited’s quoted price sits in the lower half of its reported 52-week range, 73.51% below the high.
